Companies are seeking to capitalize on a hot new gene technology, though a high-stakes patent dispute has yet to been settled. The gene-editing tool, known as Crispr-Cas9, serves as a kind of multipurpose molecular scissors that can cut DNA.
WSJ.com: Health, Wall Street Journal: Business: Health
Thu, 09/22/2016 - 7:47pm
Companies are seeking to capitalize on a hot new gene technology, though a high-stakes patent dispute has yet to been settled. The gene-editing tool, known as Crispr-Cas9, serves as a kind of multipurpose molecular scissors that can cut DNA.